Mainz Biomed is a molecular genetics diagnostic company focused on the early detection of cancer, particularly colorectal and pancreatic cancers. Their flagship product, ColoAlert®, is a non-invasive diagnostic test designed for the early detection of colorectal cancer and precancerous lesions, such as advanced adenomas. This test has shown significant clinical success in trials conducted in both the United States and Europe. The company is currently pursuing FDA approval for this product while also enhancing its offerings through collaborations, such as the recent agreement with Thermo Fisher Scientific to develop next-generation colorectal cancer screening solutions.

In addition to ColoAlert®, Mainz Biomed is developing PancAlert, an early-stage screening test for pancreatic cancer that utilizes real-time Polymerase Chain Reaction (PCR) technology to detect molecular-genetic biomarkers in stool samples. This innovative approach aims to provide effective and accessible cancer detection solutions that can be used at home, thereby transforming the landscape of cancer diagnostics. The collaboration with Thermo Fisher is expected to leverage advanced technologies and instrumentation to further enhance the development of these diagnostic tools, ultimately aiming to improve patient outcomes through early detection.

Germany

Mainz Biomed (NASDAQ: MYNZ) was founded in Germany and is becoming a leading molecular genetic diagnostics company developing market-ready molecular genetic diagnostic solutions. The company's goal is to place effective solutions in the hands of those who need them, with a focus on medical revolutions in diagnostic technology. Mainz Biomed offers genetic and genomic tests that identify the unique genetic profile of individual patients, as well as in-vitro diagnostic tests for the early detection of cancer in the United States.

Mainz Biomed

Company Details